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Introduction

Background
In 2012, the World Health Organization (WHO) updated its recommendation on influenza vaccination of health workers (HWs) concluding that ''HWs are an important priority group for influenza vaccination, not only to protect the individual and maintain health-care services during influenza epidemics, but also to reduce spread of influenza to vulnerable patient groups" [1, 2] . The WHO Global Influenza Strategy (2019-2030) reinforces this position by supporting countries to ''develop and implement national, seasonal immunization policies for HWs and other high-risk groups" [3] .
In 2017, 96 of the 194 WHO Member States reported having policies in place for influenza vaccination of HWs [4] . However, the Member States with such policies are unevenly distributed across WHO regions. Aside from mitigating seasonal influenza, influenza vaccine is considered the primary intervention to reduce mortality and morbidity in a severe pandemic. An efficient pandemic response depends largely on how well seasonal vaccine response to annual epidemics is embedded and implemented [5] .
The Review Committee on the Functioning of the International Health Regulations (2005) in relation to Pandemic (H1N1) 2009 concluded that experience with comprehensive seasonal influenza programmes would provide valuable preparation in advance of a major pandemic [6] . In November 2018, the Global Alliance for Vaccines and Immunization (GAVI) Board requested that the GAVI secretariat in collaboration with WHO assess the feasibility and impact of routine influenza immunization of HWs to support epidemic and pandemic influenza preparedness [7] .
To support these global considerations and considering the poor uptake of influenza vaccination in HWs despite the multiple reasons advocated for it as a policy, we conducted a Rapid Evidence Appraisal [8] . We aimed to capture the breadth of available evidence on influenza in health care settings and the wider health impacts of influenza vaccination in HWs. We critically appraised the literature relating to: influenza risk to HWs and the risk they pose to their patients; the benefit of influenza vaccination in HWs; and influenza vaccine uptake in HWs. By including evidence relevant to multiple stakeholders collectively -HWs, patients, and their employers -we holistically evaluated the evidence in the most policy-relevant framework as possible.
Methods
Systematic literature search
General Search Approach: The search objective was to examine the evidence under three topics using a Rapid Evidence Appraisal approach. Each topic gave rise to 2 or 3 questions for query (see Table 1 ). Evidence was queried from MEDLINE, EMBASE, CINAHL, Cochrane CENTRAL, Cochrane Reviews, WHO Global Index Medicus, National Health Service (NHS) Evidence, NHS HTA database, and multiple international clinical trials' registries. We executed three independent searches by topic with distinct search terms to capture literature for all topic questions. Search terms followed the PICO framework (population, intervention, comparators, outcomes) and studies were selected based on pre-determined criteria.
Study Types varied by review topic and question but generally included experimental or observational studies, systematic reviews, controlled observational studies, and randomized controlled trials (RCTs). Due to the volume of evidence for Topic 3 (HW vaccine uptake), literature was restricted to systematic reviews, RCTs, and evidence-based policy guidelines or toolkits. Study Outcomes were limited to laboratory-confirmed influenza as a primary outcome measure, when relevant to the queried question. Other outcomes included sickness absence incidence and/or duration, economic or productivity costs due to illness, influenzalike-illness (ILI) or respiratory illness, the number needed to vaccinate (NNV), and vaccination uptake in HWs.
Study Selection, exclusion and inclusion: Studies were selected and extracted onto a standardized template by 3 reviewers (DJ, HM, KM3) independently, defaulting to a third party (JSN-V-T) as needed. Study selection followed the following process: remove duplicates and unrelated content by title; review abstractsremove unrelated content, descriptive studies, commentaries, or studies that clearly do not meet the inclusion/exclusion criteria defined for each question; review full text -exclude based on exclusion/inclusion criteria or remove studies that lack a clear study design, methodology, or results section. Studies were then ranked according to the Maryland Scientific Methods (SMS) Quality Scale [9] with 1 being the lowest and 5 being the highest [10] . We limited the inclusion of studies to those scoring 2-5 on the quality scale published from 2006 to 2018 in whole or in summary in the English language. 
Data handling
Data Extraction: Two reviewers (DJ, KM) executed the search strategy and results were independently screened by three reviewers (DJ, HM, KM) for eligibility using a three-stage sifting approach of title, abstract and full-text. The two reviewers for 2006-2016 (DJ, HM) literature reached consensus on which search hits met the criteria for inclusion at each stage (including exclusion at the full-text stage). Any disagreements were resolved by discussion or involvement of an additional reviewer.
Data analysis: Detailed characteristics of included studies were captured and descriptively summarized in tables and figures identifying study design, population, setting, measured outcomes, results, and limitations (See Tables 2-5 ).
Literature search results
Identified literature
The collective literature search identified 3,784 publications, of which 52 individual publications met the inclusion criteria (see Fig. 1 ). Some publications addressed multiple questions resulting in a total of 60 references cited for all questions combined (see table 1 ). Of the 60 included studies, we identified 7 RCTs, 24 observational studies, 16 reviews (non-systematic or systematic), and 13 ''other" study types (see Fig. 2A and B) . Individual studies and systematic reviews were excluded from the final list of included studies (Tables 2-4) when they formed part of a more recent systematic review. These removed studies were still considered in the text if they are of moderate to high quality.
Evidence by topic and question (Tables 2-4)
Topic 1 Question 1 -Are HWs at an increased risk of influenza infection?
We identified only 1 higher quality study (4 or higher score) for this question. The review by Dini et al. [11] included 28 studies (12 systematic reviews, 13 meta-analyses, 3 appraisals) and addressed several aspects relevant to influenza vaccination in HWs, including laboratory-confirmed incidence and risk compared to controls. The review included a higher level systematic review and meta-analysis on the occupational risk of pandemic H1N1 in HWs compared to the general population or across occupations. This meta-analysis [63] evaluated 15 studies (29,358 subjects), including 11 high quality studies of laboratory-confirmed influenza, and showed a significantly increased OR = 2.08 (95% CI, 1.73-2.51) in HWs with a higher risk in physicians {OR = 6.03 (95% CI, 2.11-17.8)}.
Kuster et al. [64] , a systematic review also included in Dini et al, compared data on influenza infection rates in HWs and healthy adults from 29 surveys (n = 58,245) over 97 influenza seasons [11] . The review calculated a pooled annual incidence of 18.7% (95% CI, 15.80-22.11) per season in unvaccinated HWs versus 5.44% (95% CI, 3.01-9.84) per season in unvaccinated adults and 6.49% (95% CI, 4.63-9.09) for vaccinated HWs versus 1.20% (95% CI, 0.86-1.68) for vaccinated adults. However, this review [64] concluded the overall effect was driven by asymptomatic rather than symptomatic infections. A German study included as part of Dini et al evaluated ILI incidence combined with pre and post-season influenza serology in HWs and non-HWs [65] and concluded there was no difference in risk of symptomatic or asymptomatic influenza infection in HWs compared to non-HWs [11] . However, HWs were found to have an increased risk of clinically diagnosed acute respiratory infection (OR = 3.0, p = 0.04), and were more likely to have a pre-season antibody titre of 40 to influenza A/ H3N2, indicating the possibility of asymptomatic or subclinical influenza infections.
Five additional studies of differing methodological approach and quality provided conflicting conclusions. Three studies pointed to a higher risk [12, 13, 16] including a pandemic simulation modelling study [13] which suggested a plausible attack rate as high as 60% greater in HWs and a moderate-low quality retrospective study in Hong Kong which suggested a higher H1N1 risk in HWs and an inconclusive result when applied to seasonal influenza [12] . Sartor et al. [16] found HWs at an increased risk of influenza infection in a geriatric hospital, although the study contained fewer than 50 subjects. A moderate quality case-control study in Canada found inconclusive results on the risk of ILI in exposed HWs as did a prospective cohort study in Brazil using lab-confirmed influenza [14, 15] . Topic 1, Question 2 -Does influenza vaccination benefit HWs or their employers?
We identified several higher quality studies for this question. Two reviews compared lab-confirmed influenza in vaccinated HWs vs. controls and found a vaccine efficacy of 50-90% and a significant protective effect {Relative Risk(RR) = 0.40 (95% CI, 0.23-0.69)} [18, 66] for HWs. The high quality systematic review by Imai et al. [18] further found a reduced incidence of absenteeism due to ILI {RR = 0.62 (95%CI, 0.45-0.85)}, and a significantly shorter sick leave in the vaccinated group {RR = 0.46 (ILI + labconfirmed), RR = 0.60 (lab-confirmed)}. The study concluded that vaccination provided a protective effect in HWs and deemed vaccination programs as cost-saving. The widely-cited studies by Kliner et al. [66] and Kuster et al. [64] were included in the appraisal by Dini et al who identified 6 reviews relevant to this question [64, [66] [67] [68] [69] [70] and also concluded that vaccination was protective and potentially cost-saving in HWs [11] .
Two contradictory RCTs included a Malaysian study that [28] found reduced absenteeism (12 days vs. 52 in the control group, p = 0.002) and ILI (reduced by 52.6%, p = 0.002) due to vaccination, using all self-reported outcomes. A Dutch RCT [25] actually found an increase in absenteeism in the vaccinated groups {2009/10 (4.6% vs 3.4%); 2010/11 (4.6% vs 3.9%)}, although they attributed the increase to more frequent testing for influenza in the intervention cluster and the study was performed during periods of H1N1pdm09 activity in 2009-2011.
We identified 8 observational studies of moderate to lower moderate quality [19] [20] [21] [22] [23] 26, 27, 30] , 5 of which found a vaccine benefit to HWs or employers and 3 which found no benefift or inconclusive results. A study in a large Italian hospital found an increase in absenteeism [19] Three studies suggested no benefit including a prospective cohort study in Israel [23] which found HWs less likely to develop lab-confirmed influenza, although this finding was not significant. A study in Kenya [26] found vaccinated participants were more likely to develop acute respiratory illness (ARI) and more likely to miss work after vaccination. A large retrospective ecological study [20] evaluated 800,000 HWs per year over 4 flu seasons in England and found that a 10% increase in vaccine uptake would lead to a decrease in approximately 0.43 percentage points in the absolute sickness absence rate (from 4.5% to 4.07%), or a 10% relative decrease in the sickness rate. Studies looking at the costbenefit of vaccination generally found HW vaccination to be costsaving and of economic benefit from the perspective of the employer [18, 24, 28, 29] .
Topic 2, Question 1 -Do HWs transmit influenza to patients? Evidence varied widely in methodological approach, yet some findings suggest HWs are at least one of the sources of transmission. We identified moderate to higher quality studies which implicated HWs in some transmission events, particularly in geriatric patients, in acute care settings during flu season [31] [32] [33] and during hospital outbreaks [36] . These studies utilized technologies such as wearable sensors [31, 34] , molecular-based subtyping methods [32] , or phylogenetic analyses combined with case studies or epidemiology [35, 40] . One retrospective cohort study analyzed routes of transmission among HWs and geriatric patients using molecular-based subtyping methods. The study identified three nosocomial outbreak clusters within one 'outbreak' and found a higher influenza incidence in patients (24%) than in HWs (11%) [32] . A large nosocomial outbreak in a geriatric hospital [35] used detailed case studies combined with phylogenetic analysis to reveal 5 clusters of cases and multiple introductions of community strains into the hospital. Similarly, a study by Valley-Omar et al. [40] in South Africa combined epidemiological investigation with phylogenetic analysis to study influenza transmission chains and the extent of nosocomial transmission over a four-month period within a pediatric hospital. This analysis found that most potential nosocomial infections resulted from multiple introductions of Influenza A into the hospital and suggested transmission between asymptomatic patients, HWs, and visitors.
Topic 2, Question 2, Part A -Does influenza vaccination in HWs benefit patients?
We identified two higher quality studies relevant to this question [11, 25] , and several lower quality studies using ILI [43] [44] [45] as an outcome measure. The comprehensive review by Dini et al.
[11] evaluated 6 systematic reviews [66, 69, [72] [73] [74] 76] and found overall inconclusive results as studies were of moderate but mostly lower quality, evaluated the same 4 RCTs [77] [78] [79] [80] , and came to different conclusions. The review included the latest version of a Cochrane Systematic Review by Thomas et al. [74] which evaluated these 4 highly cited RCTs in long term care facilities (LTCFs) [77] [78] [79] [80] . However, different from prior reviews by the same author, this time they excluded all-cause mortality as an outcome measure (only influenza-related outcomes) and found no conclusive evidence of the benefit of HW vaccination to LTCF residents. They also found a low quality of evidence with a high risk of bias. Another systematic review and meta-analysis [76] included in Dini et al pooled data from 4 RCTs and suggested a benefit to all-cause mortality {RR = 0.71 (95% CI, 0.59 -0.85)} and ILI {0.58 (95% CI, 0.46 -0.73)}, but all-cause hospitalization and laboratory-confirmed influenza were not statistically significantly altered [11] .
Although we identified 5 higher quality clustered randomized controlled trials (cRCTs) [25, [77] [78] [79] [80] which address this question, only the Dutch trial [25] was not included in prior reviews (per our exclusion criteria), other than in de Serres et al. [73] in the next section, illustrating the need for updated cRCTS. This pragmatic cRCT [25] measured rates of nosocomial infection as a secondary outcome in 2 high risk departments -pediatrics and internal medicine. Within the higher vaccine coverage groups of the internal medicine departments, nosocomial influenza and/or pneumonia was recorded in 3.9% compared to 9.7% in the control hospitals, respectively (p = 0.015). An increase in vaccine coverage was associated with decreased inpatient morbidity from influenza and/or pneumonia in internal medicine settings, but not in pediatrics.
Topic 2, question 2, Part B -How many HWs need to be vaccinated (NNV) to ensure a benefit to patients?
We found a limited number of moderate quality observational and modelling studies [46] [47] [48] [49] [50] [51] which suggest that a proportionate effect of HW vaccination is likely, where nosocomial influenza infections decrease with increasing HW vaccination coverage. Salgado et al. [47] conducted a retrospective cross sectional study in a USA tertiary care hospital over 12 consecutive years. HW vaccination rates increased from 4% in 1987-1988 to 67% in 1999-2000 (P < 0.0001). Proportions of nosocomial influenza cases among employees or patients both declined significantly (P < 0.0001). Logistic regression analysis revealed a significant inverse association between HW compliance with vaccination and the rate of nosocomial influenza among patients (P < 0 0.001). The authors reported that surveillance of nosocomial spread and isolation poli- cies remained constant during the study period, but concomitant increase in patient influenza vaccination rates may have contributed to the decrease in nosocomial infections. A nested-case control study [75] included in the review by Seal et al. [42] found that a vaccinated proportion of 35% of HWs in short-stay units appeared to protect against nosocomial influenza among patients (OR = 0.07; 95% CI, 0.005-0.98) independent of patient age, influenza season and potential influenza source. The authors concluded that a minimum of 35% vaccination coverage in HWs would be required to have a potential protective impact on hospitalacquired influenza infection. Dini et al. [11] also included a review by de Serres et al. [73] who used the mathematical principal of dilution as the basis for their re-examination of the main 4 cRCTs used as evidence for mandatory vaccine policies in HW [77] [78] [79] [80] . They disputed the NNV (number needed to vaccinate) of 8 found by Hayward in 2006 in LTCF settings [79] and recalculated it to be 36,000, which was quickly disputed by Hayward [81] . Hayward stressed that results from their study in LTCFs were not necessarily applicable outside of the most frail and vulnerable patients.
In two modelling studies by van den Dool et al. [48, 49] , one model in LTCFs predicted ''a robust linear relationship between the number of HWs vaccinated and the expected number of influenza infections in patients, preventing 60% of influenza virus infections among patients" (NNV = 7). Comparing these results in LTCFs to a hospital or short stay setting, they found an equivalent or higher estimate of impact in hospital patients (NNV = 3) and that vaccination of 100% of HWs would potentially prevent 40% of inpatient nosocomially acquired influenza infections.
Topic 3, Question 1-What are the successful and practical interventions which increase HW influenza vaccine uptake?
We identified several higher quality RCTs and systematic reviews addressing this question and there is consensus that no single intervention component has been found to rapidly and substantially raise influenza vaccination rates in HWs, aside from mandatory vaccination [82] . However, several systematic reviews [52, 59, 83] and tool kits [57, 58] have highlighted that multifaceted approaches which sustain over time can see increases > 90% [47] . Dini et al. [11] evaluated 7 systematic reviews which together evaluated strategies to increase uptake in HWs in > 200,000 subjects. They found that some successful alternatives to mandatory vaccination included ''soft-mandates", such as masks, ''opt-out", or declinations statements, and multi-faceted programmes which take into consideration the local context, include incentives, education, advertising, and easy vaccine access as efforts to enhance behavior change.
Higher level systematic reviews had similar findings including a meta-regression analysis that [83] found that the single most successful strategies after mandatory vaccination were ''soft" mandate strategies and a policy excluding non-vaccinated HWs from working with highly vulnerable patient groups. Another systematic review [52] found that successful interventions contained the following critical components: free and easy access to vaccine; knowledge and behavior change through educational activities; reminders and incentives; management/organizational approaches including personnel charged with implementing the programme; and a long-term strategy. An additional study of 121 publications also concluded that all interventions increased uptake to some extent with the most successful being those which required vaccination as a condition of being allowed to work [84] .
Several randomised trials [85] have successfully used a preintervention survey as a basis for subsequent intervention mapping [25, 86] in the development of multi-faceted interventions. This is particularly important as the reasons for vaccine hesitancy are complex and heterogeneous [52] , making local, social, cultural, institutional and logistical factors all relevant to the development of educational or knowledge-based interventions. Other RCTs failed to dramatically raise uptake using educational tools or manuals and a decision aide intervention which changed views but not actions [54] [55] [56] .
Topic 3, Question 2 -What are the sociological, behavioural, and public health policy aspects of influenza vaccine uptake in HWs?
We identified 3 higher moderate studies on this topic, including two reviews [11, 61] . One review [11] evaluated 16 systematic reviews on vaccination determinants in HWs, adherence to vaccination, and risk perceptions or beliefs about vaccination. The study broadly found the following: knowledge about influenza varied by occupation, not necessarily occupational level (doctors vs. dentists for example); many misconceptions about influenza persist, even though influenza knowledge has improved over time; the relationship between HWs' perception and mitigation of risk is complex and multi-factorial and needs to be better understood. Included as part of this review was a large systematic review by Schmid [86] which included 470 studies, of which 117 looked at HW barriers to influenza vaccine uptake. Their review found that micro-level determinants included age, gender, additional risk factors, and past behavior as the most reported factors to influence uptake. They further evaluated the determinants based on the 4C model for vaccine hesitancy (complacency, confidence, convenience, and calculation) and found that the strongest barrier to uptake was a HWs lack of confidence about disease severity or vaccine effectiveness and ''a lack of professional or ethical obligation to get vaccinated". This was in line with the systematic review by Hollmeyer which found that HWs are motivated to be immunized against influenza more often for their own benefit than for the benefit of their patients [52] .
Lorenc et al. [61] conducted a systematic review of 25 studies on HWs' beliefs and perceptions about vaccination within different contexts and found that many participants are unsure of the real value of vaccination programs. This study highlighted that the success of a vaccination program may be influenced by the complex relationship between HWs and the organization and management of the health care system within which they work. Ofstead and colleagues [62] executed a three-part evidence-based intervention study in LTCFs which compared a multi-faceted ecological model and the health belief model. They raised uptake from 50% to 85%, decreased respiratory illness-related absenteeism by 12% and concluded that an ecological model was more effective than the health belief model at increasing uptake as it includes broader policy or organizational aspects relevant to program implementation.
Discussion
We executed a Rapid Evidence Appraisal [8] of the literature from 2006 to 2018 to evaluate the evidence relevant to the ongoing discussions about seasonal influenza vaccination in HWs. Influenza infection and vaccination in HWs poses a complex policy challenge due to the general lack of high quality evidence, the inherent complexity of influenza, and the number of potential benefactors: HWs themselves by avoiding influenza infection, their patients by virtue of reduced influenza transmission in health facilities, their employers in terms of business continuity, and potentially their families and wider community contacts.
Influenza risk to health workers
The evidence on whether HWs are at increased risk of influenza infection (symptomatic and asymptomatic) in HWs is mixed. Recent studies suggest a higher risk with pH1N1 [11] [12] [13] 63] , a high attack rate, and variations in risk which are connected to occupa- tional exposure. Other studies find a risk to patients and HWs during an outbreak [16] and following contact with ILI patients [15] . Additional studies suggest only a risk of asymptomatic infection [17, 64] . Taken together, these studies highlight that setting [88] , occupation [89] or patient contact level, risk procedure [90] , circulating virus, and existing immunity in the population (i.e. H1N1) can all vary risk [63] . However, respiratory illness has been reported as one of the main causes of sickness absence in HWs [92, 91] , pandemics and epidemics can be associated with concurrent increased rates of HW absenteeism [12, 92, 93] , and HWs do overall appear to be at risk of contracting influenza.
Vaccine benefit to health workers or their employers
Recent higher level evidence [11, 18] evaluating RCTs, cohort studies, and systematic reviews does suggest a vaccine benefit to HWs and their employers including a protective effect against laboratory-confirmed influenza, shortened sick leave, and a reduced incidence of absenteeism (due to ILI). However, vaccine benefit studies during the years of pH1N1, including an RCT in the Netherlands, found the opposite effect, an increase in absenteeism in the vaccination arms. Different authors draw contradictory conclusions from the use of the same RCTs [94] [95] [96] , indicating a need for updated, large scale studies of higher quality. Observational studies also draw different conclusions and are constrained by poor study design, non-specific outcomes, a high risk of bias, and failure to adjust for confounding factors. Absence due to ILI is frequently used as an outcome measure when ILI itself has relatively poor predictive value for influenza infection [97, 98] . Although studies may provide contradictory conclusions, vaccine efficacy in HWs has been shown to be as high as 90% for wellmatched seasonal influenza vaccines [66, 68] , and high for pandemic vaccine [99] . Therefore, it seems reasonable that vaccinating HWs against influenza will reduce influenza burden in HWs, related work absenteeism, and possibly influence subclinical infection and/or ''presenteeism" -attending work whilst ill.
Influenza risk to patients
The expanding volume of studies combining epidemiological and phylogenetic analysis, among other new technologies [71, 72] , suggest that HWs are implicated in at least some transmission during nosocomial outbreaks of influenza. However, the complexity of transmission in health facilities is also driven by various factors including patient to patient and visitor to patient contact, varying levels of possible infectiousness with asymptomatic vs. symptomatic transmission, and high patient turnover, particularly in acute care settings [37, 38, 40] . Nevertheless, Pagani et al. [35] identified multiple introductions of strains into the hospital from the community during an outbreak and noted that unvaccinated HWs may have played an important role in sustaining the outbreak. Other factors which may increase or decrease the extent to which HWs are implicated in transmission are individual (immune status, severity of disease, viral shedding), pathogen (virulence, infective dose), and environmental factors (infection control practices, ward layout, frequency of patient, staff and visitor contacts), including contact with HWs of varying degrees of risk exposure themselves. Notwithstanding, the evidence does suggest that HWs can clearly pose a transmission risk to patients, at least some of the time.
Vaccine benefit to patients
The benefit of HW influenza vaccination to patients is not clear or consistent in the literature and continues to be debated as numerous systematic reviews using mostly the same RCTs [77- [11, 66, 73, 76] . Research in LTCFs has consistently shown a benefit to patients, at least for all-cause mortality. Variations across study populations or studies, such as patient populations, level of HW to patient contact, patient vulnerability or susceptibility, or levels of risk exposure for HWs themselves, limit comparability between findings. This may explain why studies in LTCFs consistently find vaccination of HWs beneficial to elderly patients, where the stability of the setting, patient characteristics, and high level of contact between HWs and patients are all consistent factors. Whereas, a larger body of evidence suggests an unclear association between HW vaccination and patient benefit in hospital settings, which may be due to variations in study design, HW or patient characteristics, their individual risk or susceptibility, difference in vaccine type or diagnostic testing, or even the time of year. LTCF patients do however appear to benefit, at least regarding mortality, which demonstrates that vaccine benefit to patient warrants efforts to increase vaccination in HWs caring for the elderly [100] .
Influenza vaccine uptake
The factors that feed into a HWs decision-making pathway for influenza vaccination are diverse and individually-driven [52] . Therefore, any efforts must be as equally diverse as the HWs they target. Mandatory vaccination is debated extensively from many perspectives including the reasons for [21] and against it [73] ; however, no amount of debate can refute that mandatory vaccine policies do raise uptake quickly, usually to levels in excess of 94-96% [82] . Other successful interventions are multi-faceted, sustained over time [47] , and evolve over time as data is collected on the target population [85] . These make vaccine easily accessible, maintain strong organizational support, develop education which varies by targeted groups, and may include ''soft-mandate" policies, such as declination statements, or alternatives such as masks [52, 83] .
One area which deserves more consideration, is the use of different types of models in the development of interventions to improve uptake. Traditionally, the health belief model is most commonly used. However, studies exploring other possibilities [62, 86] have shown promise with an ecological model, which takes into consideration the contextual, organizational, policy or background components which are relevant to a vaccine program and henceforth to a HWs decision to take the vaccine. These models incorporate the growing understanding that HW vaccine uptake involves much more than individual knowledge, attitudes, and beliefs. The greater context of the HW and their relationship to the organization, other HWs, and broader cultural factors are all important to vaccine uptake.
Study limitations
Although we made every effort to execute an unbiased and systematic approach to our search and selection of included literature, our study was not without limitations. Due to resource and time constraints, we limited the search to English language abstract or full-text articles, did not include grey literature, and removed publications that were included as part of a more recent systematic review. This may have led to some selection bias and limited our exposure to all relevant articles. However, due to the breadth of questions included in the search and the execution of three distinct searches, we felt that this diversification may have added strength to the study design to compensate for this weakness.
The majority of included studies were observational studies, which limits the strength of our findings as observational studies are susceptible to bias and there is limited ability to infer causality. Additionally, many studies were executed in different types of settings, with different target populations, using different vaccines and with varying levels of risk or exposure to the populations being studies. This makes comparing across studies very difficult.
Our methodology lacks the robustness of a formal systematic review or meta-analysis and does not report on effect size. Systematic reviews have very defined limitations for study selection and inclusion and typically do not query so many questions. We executed a Rapid Evidence Appraisal -a time-limited effort of assessing the evidence to draw conclusions, a process similar to what might happen in a 'real-life' policy environment. To compensate, we approached the literature search in a systematic way to add robustness to our study design and the breadth of our included questions and consideration of multiple elements relevant to the decision-making process, offers a more realistic approach for policy makers. Finally, our study was adapted and updated from a white paper originally intended to advise and inform WHO when establishing the influenza vaccine research agenda. The objective was to support global policy recommendations. 
Conclusion (see summary of findings Table 5)
In recent years, several comprehensive reviews [11, 18, 42, 61, 64, 66, 67, 73, 74, 76, 83, 86, 87] have attempted to rigorously address different aspects of influenza vaccination in health workers. Paradoxically, the number of reviews far outweighs the number of studies that are of high quality or give definitive answers. Similarly, our review included only RCTs that have not already been evaluated as part of a more updated systematic review. It is therefore hardly surprising that it has proved difficult to draw universal and emphatic conclusions for policy makers, government leaders, and healthcare managers; and that implementation is poor and acceptance low.
Nevertheless:
Nosocomial influenza is a recognized problem and it is clear there is a problem to solve or a case to answer.
There is adequate evidence that HWs contract influenza and data suggests they are at risk of continuing to work whilst infected.
There are sufficient data to conclude that influenza vaccines are as effective in HWs as in other adults of similar age. Data are emerging that capture the complexity of influenza transmission in health facilities and new molecular evidence implicates HWs in transmission events. Data on whether vaccinating HWs protects patients is of mixed quality and does not universally favor a positive (protective) outcome. However, there are strong signals from studies in LTCFs that HW vaccination protects patients, especially with regard to mortality.
The evidence base requires improvement and future research should aim to evaluate the impact of HW vaccination on clearly defined and standardized outcome measures in specific cohorts of beneficiaries. A better understanding of transmission dynamics across a diversity of HW and patient risk groups is needed to facilitate a more nuanced and useful estimation of the wider benefits of HW influenza vaccination. The large body of knowledge on effective ways to increase vaccine uptake in HWs needs to be incorporated consistently within vaccination policies and practices. Programmes will need to consider the importance of organizational and contextual factors as drivers alongside the individual perceptions of HWs. The evidence demonstrating the effectiveness of mandation in improving uptake is however emphatic.
Influenza is likely to persist as a unique methodological challenge for researchers to produce reliable and robust results which lead to definitive conclusions about HW vaccination. Influenza burden, infectiousness, and severity vary yearly, seasonally, and spatially. Influenza risk also varies by setting, such as in proximity to young children or immune-compromised individuals, and by occupation or activity (such as performing respiratory procedures on infected patients). Additionally, influenza vaccine effectiveness is equally variable by season and subtype, making comparisons between years and populations challenging.
Due to the inherent complexity of influenza, waiting for the perfect results with influenza risks decision paralysis. When considering the evidence with a 'whole-of-system' approach, rather than considering specific evidence questions in isolation, we argue that the case for vaccinating HWs against influenza is maintained. Furthermore, to ensure the success and likelihood of expansion of seasonal influenza programs globally, guidance is needed for policy makers and implementers on how to best integrate influenza vaccination to HWs within existing vaccination and occupational health frameworks.
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